RecruitingNot ApplicableNCT07068399

Use of Shock Wave Therapy for Neo-Vascularisation in Non-critical Coronary Artery Disease: Validation by Quantitative Cardiac MRI Perfusion

Sponsor

The University of Hong Kong

Enrollment

100 participants

Start Date

Sep 1, 2020

Study Type

INTERVENTIONAL

Conditions

Coronary Artery Disease

Summary

This is a randomised controlled trial aimed to demonstrate the effect of cardiac extracorporeal shock wave therapy (CSWT) on the angiogenesis effect of myocardium by determining myocardial perfusion and left ventricular function in patients with coronary artery disease (CAD) when measured by cardiac MRI before and after the treatment.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria3

Patients with symptoms of coronary artery disease
Patients without obstructive coronary artery disease
with LVEF not < 40%.

Exclusion Criteria8

Age < 18 years,
Pregnancy or lactation.
Contraindication to contrast enhanced stress Cardiac Magnetic Resonance (eg. Estimated GFR <30ml/min/1.73m2, severe allergy to gadolinium based contrast agent, contraindication to adenosine)
Life expectancy <24 months
Haemodynamically unstable
Participation in other clinical trial within 6 months of enrollment.
Recent myocardial infarction within 6 months.
Unable to consent to or perform components of the study.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREExtracorporeal shock wave therapy

Extracorporeal shock wave therapy (ESWT) delivers acoustic energy transmitted through liquid medium to internal body tissues. The intervention group will receive a total of 9 ESWT treatment sessions and 200 shocks will be applied to each ischaemic zone of myocardium for 3 times a week on the three weeks that the patients receive ESWT.